How quickly time passes, especially during the summer months! It seems only like yesterday that we wished all of our readers a wonderful vacation season and announced our usual summer break in publishing this newsletter for the months of July and August. As we are writing this introduction to our September VOICE, the end of summer is upon us and, before we know it, we will be speeding toward the year-end holiday season. One reason why here at CHR the summer months passed so quickly this year was that they were unusually busy clinically. We, therefore, also expect a busier fall season than usual. With summer vacations over, we are back to full manpower, and are looking forward to the challenges.
When it comes to medically relevant news, the summer months this year were surprisingly quiet. Only one subject that made headlines over the summer got our writers’ fingers a bit itchy but, ultimately, was not considered worth interrupting the VOICE’s summer hiatus; and that was the disturbing story that some fertility centers, through direct-to-public genetic testing, were found to have used their own physicians’ semen in place of semen from sperm donor agencies, as had been represented to patients. We are addressing this subject in this newsletter, together with another development that caught the attention of the media: colleagues down the street at Weill-Cornell starting to experiment with genetic editing of sperm that carries abnormal mutations using CRISPR/Cas-9. As always, we also address issues our readers raised, such as causes and prevention of early miscarriages (our lead article), the so-called lymphocyte immunization to prevent miscarriages and a new treatment developed at CHR, which we’ve termed “rebound.”
In this issue of the CHR VOICE, we cover:
- Causes of early miscarriages at 6-8 weeks
- Early miscarriage risk factors and testing for early miscarriage risks
- Preventing early miscarriages at 6-8 weeks
- Reproductive endocrinologists as sperm donors
- Lympcyte immunization therapy to prevent miscarriages?
- Gene editing of sperm via CRISPR/Cas-9
- “Rebound” effect after poor response to IVF medications
- CHR in the media